Recent News

SciFluor News

SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience
read more >

SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
read more >

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders
read more >


SciFluor Life Sciences is a drug discovery company developing a broad portfolio of differentiated best-in-class therapeutics to treat various diseases.

The company creates patentable new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, dosing, and patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a diverse range of therapeutic categories and disease areas including retinal disease, CNS disorders, pain, and respiratory and inflammatory diseases. We are advancing selected development candidates into clinical studies and actively seeking industry partners to drive the development and commercialization of our innovative new medicines.

SciFluor was established in 2011 by Harvard University and Allied Minds.